Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 18, 2024LifeOpen Access

Applied Cardio-Oncology in Hematological Malignancies: A Narrative Review

View Full Paper
Ask AI
Bookmark
Share

Population

Patients with hematological malignancies, particularly leukemia, lymphoma, and multiple myeloma

Design

Narrative review

Authors

EMEvdokia MandalaKLKyranna LafaraDKDimitrios Kokkinovasilis

Discussion

Loading...

Member takes

Overview

May inform cardiotoxicity monitoring in hematologic malignancies; leaves open need for prospective validation of imaging and biomarkers.

Structured PICO

P
Population
Patients with hematological malignancies, particularly leukemia, lymphoma, and multiple myeloma
I
Intervention
Hematological cancer therapies including conventional chemotherapy, targeted therapy, immunotherapy, chimeric antigen receptor T (CAR-T) cell and tumor-infiltrating lymphocyte therapies, bispecific antibodies, and hematopoietic stem cell transplantation

This narrative review provides a comprehensive overview of cardio-oncology principles applied to patients with hematological malignancies, focusing on the detection and management of therapy-related cardiotoxicity.

Cite This Study

Mandala et al. (2024) studied this question.

synapsesocial.com/papers/6a80f0e6da9cafc35e33774dhttps://doi.org/10.3390/life14040524
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Cardiotoxicity of Biological Therapies in Cancer Patients: An In-depthReview2022 · 16 citations
  2. 2Role of advanced cardiovascular imaging in chemotherapy-induced cardiotoxicity2023 · 23 citations
  3. 3Rationale and Design of the Cardiac CARE Trial: A Randomized Trial of Troponin-Guided Neurohormonal Blockade for the Prevention of Anthracycline Cardiotoxicity2022 · 12 citations
  4. 4PET Tracers for Imaging Cardiac Function in Cardio-oncology2022 · 28 citations
  5. 52022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)2022 · 516 citations